home > ict > summer 2021 > clinical trial supply chains accelerated by labelling innovation
International Clinical Trials

Clinical Trial Supply Chains Accelerated by Labelling Innovation

Following the successful development, testing, and rollout of several COVID-19 vaccines in less than a year, might we be seeing a shift in expectations for drug discovery and development? Some will ask, why does it take 5 to 10 years for a molecule to make it to market when vaccines have been developed in around 12 months?

Undoubtedly, a global pandemic offers unique conditions, yet some of the innovations deployed to successfully manage rapid clinical trials and accelerate the supply chain can be transposed almost universally. It’s PRISYM ID’s view that COVID-19 brought the life science supply chain closer together than ever before. As a result, new capabilities and levels of service should now become more routine.

Trial Delays and Need for Flexibility

Clinical trials are expensive endeavours, and the postponement of any phase can be incredibly costly as the data are needed to secure the next round of funding. Despite their essential nature, labels and booklets can be an afterthought when considering potential improvements to the supply chain. However, when an external supplier with a two- to three-week lead time is tasked with making yet another last-minute content change, this creates an unnecessary delay.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


PRISYM ID provides regulated content and label management solutions designed specifically for life science companies and medical device manufacturers, improving patient safety and health outcomes while ensuring regulatory compliance. PRISYM ID’s unique products and technologies are used to assure compliance globally, for 10 million+ medical device, clinical trial, and pharmaceutical products annually.
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG ‘Makes it Better’

ACG is consolidating its founding values of caring, collaboration and progressiveness in a comprehensive re-brand. As one of the world's leading suppliers of fully integrated solutions to the global pharmaceutical and nutraceutical industry, ACG is taking this opportunity to share the message at the heart of its operation - ‘Make it Better’
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B


Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement